By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Advicenne 

2, rue Briçonnet

Nîmes    F-30 000  France
Phone: 33-466-05-54-20 Fax: 33-466-21-23-35


SEARCH JOBS

Advicenne is a late-stage biopharmaceutical company focusing on the development of paediatric friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company has a strong portfolio of products in late-stage development targeting critical unmet needs in nephrology and neurology. Advicenne also develops a clinical and pre-clinical pipeline of potential treatments for additional orphan diseases in collaboration with Key Opinion Leaders.

YEAR FOUNDED:

2007

LEADERSHIP:

Founder and CEO: Luc-André Granier

CBO: Ludovic Robin

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Private

Web Site: Advicenne
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
Advicenne To Present A Poster At The 9th EuPFI Conference On ADV7103, An Innovative Age-Adapted Product For Distal Renal Tubular Acidosis (dRTA) 9/22/2017 8:13:27 AM
Advicenne Announces Positive Pivotal Phase III Clinical Data For ADV7103 In Adults And Children Suffering From Distal Renal Tubular Acidosis (dRTA) 9/12/2017 11:35:53 AM
Advicenne Announces Positive Pivotal Phase III Clinical Data For ADV7103 In Adults And Children Suffering From Distal Renal Tubular Acidosis (dRTA) 9/11/2017 8:07:30 AM
Advicenne Receives Orphan Drug Designation From The EU For ADV7103 For The Treatment Of Distal Renal Tubulopathy 7/5/2017 9:27:38 AM
Advicenne To Present Preliminary Phase III Clinical Data On ADV7103 At The Upcoming European Society Of Pediatric Nephrology’s Annual Meeting 6/22/2017 10:59:05 AM
Advicenne Announces The Closing Of A €16 Million Financing Round 3/20/2017 8:56:10 AM
//-->